Protein-Tyrosine Kinase; Rheumatoid-Arthritis; Interferon-Alpha/Beta; Cardiovascular Events; Psoriatic-Arthritis; Cancer-Risk; Tofacitinib; Metaanalysis; Mortality; Inflammation Rheumatoid arthritis (RA) is a systemic, chronic, immune-mediated inflammatory condition. Treatments options encompass conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic disease-modifying antirheumatic drugs (bDMARDs) like tumor necrosis factor (TNF) inhibitors (TNFis) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) including Janus Kinase inhibitors (JAKinibs). Orally administered JAKinibs have demonstrated comparable or, in specific cases, superior efficacy compared to bDMARDs in inflammatory conditions. However, the escalating clinical utilization has been accompanied by the emergence of serious adverse effects, including major adverse cardiac events (MACE), malignancies and venous thrombotic episodes (VTE), leading to regulatory restrictions imposed by health authorities in both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). CC BY-NC 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ 2024 Dove Medical Press Ltd eng Wlassits, Rebekka (Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie) Müller, Mathias (University of Veterinary Medicine Vienna) Fenzl, Karl H. (Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie) Lamprecht, Thomas (Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie) Erlacher, Ludwig (Karl Landsteiner Institut für Autoimmunerkrankungen und Rheumatologie) JAK-Inhibitors - A Story of Success and Adverse Events Open Access Rheumatology - Research and Reviews 16, 43-53 (2024) doi:10.2147/OARRR.S436637 https://phaidra.vetmeduni.ac.at/o:2951 application/pdf article